Key Points
- CEO William John Sibold sold 1,663 shares at an average price of $431.94 for roughly $718,316, reducing his holding by about 1.02% to 161,829 shares.
- Multiple senior insiders also sold shares, including CFO Mardi Dier (1,982 shares, ~13.7% reduction), indicating a broader insider sell-off beyond the CEO.
- For context, Madrigal reported a quarterly ($2.57) EPS miss despite revenue of $321.1M (up 210.8% YoY); the stock trades near $432.83 and carries a consensus "Moderate Buy" rating with an average price target of $685.31.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) General Counsel Shannon Kelley sold 360 shares of the firm's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $431.94, for a total value of $155,498.40. Following the transaction, the general counsel directly owned 12,138 shares in the company, valued at approximately $5,242,887.72. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Madrigal Pharmaceuticals Stock Performance
Shares of MDGL traded down $6.51 during midday trading on Friday, reaching $432.83. 440,127 shares of the stock were exchanged, compared to its average volume of 375,225. Madrigal Pharmaceuticals, Inc. has a twelve month low of $265.00 and a twelve month high of $615.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77. The company has a market capitalization of $9.93 billion, a price-to-earnings ratio of -33.63 and a beta of -0.97. The business's 50-day moving average price is $492.64 and its 200 day moving average price is $486.72.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($2.61). The firm had revenue of $321.08 million during the quarter, compared to analyst estimates of $310.36 million. Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The firm's revenue for the quarter was up 210.8% compared to the same quarter last year. During the same period last year, the company earned ($2.71) earnings per share. On average, sell-side analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
MDGL has been the topic of a number of research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, January 22nd. Wolfe Research set a $579.00 price target on shares of Madrigal Pharmaceuticals in a research report on Tuesday, January 6th. TD Cowen reissued a "buy" rating on shares of Madrigal Pharmaceuticals in a research report on Monday, January 12th. HC Wainwright lifted their price objective on shares of Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the company a "buy" rating in a research note on Friday, November 21st. Finally, Oppenheimer upped their target price on shares of Madrigal Pharmaceuticals from $600.00 to $650.00 and gave the company an "outperform" rating in a report on Thursday, November 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $685.31.
Get Our Latest Research Report on MDGL
Madrigal Pharmaceuticals News Roundup
Here are the key news stories impacting Madrigal Pharmaceuticals this week:
- Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
- Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
- Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
- Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
- Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
- Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
- Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of MDGL. Eastern Bank raised its stake in shares of Madrigal Pharmaceuticals by 32.3% during the fourth quarter. Eastern Bank now owns 86 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 21 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Madrigal Pharmaceuticals by 0.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 4,459 shares of the biopharmaceutical company's stock worth $1,349,000 after purchasing an additional 30 shares during the period. Centaurus Financial Inc. grew its position in Madrigal Pharmaceuticals by 5.0% in the 3rd quarter. Centaurus Financial Inc. now owns 709 shares of the biopharmaceutical company's stock valued at $325,000 after buying an additional 34 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Madrigal Pharmaceuticals by 34.6% in the 4th quarter. Farther Finance Advisors LLC now owns 140 shares of the biopharmaceutical company's stock valued at $82,000 after buying an additional 36 shares during the period. Finally, Accent Capital Management LLC increased its stake in Madrigal Pharmaceuticals by 64.9% in the 4th quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company's stock valued at $55,000 after buying an additional 37 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company's pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.
The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
